# EDGAR Filing Document

**Accession Number:** 0001017491
**File Stem:** 0001104659-23-030734
**Filing Date:** 2023-3
**Character Count:** 34810
**Document Hash:** 493407791188c2717d3daf3b6a47f0e5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-030734.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001104659-23-030734

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230309

**EFFECTIVENESS DATE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SEELOS THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001017491
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 870449967
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270435
- **FILM NUMBER:** 23721409

**BUSINESS ADDRESS:**
- **STREET 1:** 300 PARK AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** (646) 293-2100

**MAIL ADDRESS:**
- **STREET 1:** 300 PARK AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** APRICUS BIOSCIENCES, INC.
- **DATE OF NAME CHANGE:** 20100914

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NEXMED INC
- **DATE OF NAME CHANGE:** 19970311

**As filed with the Securities and Exchange Commission on March 9, 2023**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

------

**Seelos Therapeutics, Inc.**

**(Exact name of Registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Nevada** | **87-0449967** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**300 Park Avenue, 2nd Floor**

**New York, NY 10022**

**(Address of principal executive offices, including zip code)**

------

**Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan**

**Seelos Therapeutics, Inc. 2020 Employee Stock Purchase Plan**

**(Full title of the plans)**

**Raj Mehra, Ph.D.**

**President, Chief Executive Officer and Chairman of the Board of Directors**

**Seelos Therapeutics, Inc.**

**300 Park Avenue, 2nd Floor**

**New York, NY 10022**

**(646) 293-2100**

**(Name, address and telephone number, including area code, of agent for service)**

------

***Copies to:***

**Jeffrey T. Hartlin, Esq.**

**Paul Hastings LLP**

**1117 S. California Avenue**

**Palo Alto, California 94304**

**(650) 320-1800**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | x | Smaller reporting company | x |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**REGISTRATION OF ADDITIONAL SECURITIES**

**EXPLANATORY NOTE**

Seelos Therapeutics, Inc. (the "Registrant") has prepared this registration statement (this "Registration Statement") in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended, to register: (1) 4,771,457 additional shares of Common Stock issuable pursuant to the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the "2012 Plan"), and (2) 1,063,421 shares of Common Stock issuable pursuant to the Seelos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP"). The 2012 Plan and the ESPP, including the shares of Common Stock available for issuance pursuant thereto, have each been previously approved by the Registrant's stockholders.

Pursuant to the Registration Statements on Form S-8 (File Nos. [333-182704](https://www.sec.gov/Archives/edgar/data/1017491/000114420412039699/v318703_s8.htm), [333-191680](https://www.sec.gov/Archives/edgar/data/1017491/000119312513396722/d611202ds8.htm), [333-204748](https://www.sec.gov/Archives/edgar/data/1017491/000101749115000058/a2015s-8.htm), [333-210040](https://www.sec.gov/Archives/edgar/data/1017491/000101749116000114/a2016s-8.htm), [333-215419](https://www.sec.gov/Archives/edgar/data/1017491/000101749117000002/a2017s-8.htm), [333-218368](https://www.sec.gov/Archives/edgar/data/1017491/000101749117000080/a2017s-8restatedplan.htm), [333-229846](https://www.sec.gov/Archives/edgar/data/1017491/000113626119000081/s8body.htm), [333-238562](https://www.sec.gov/Archives/edgar/data/1017491/000113626120000135/s8body.htm), [333-255670](https://www.sec.gov/Archives/edgar/data/1017491/000113626121000065/s8body.htm) and [333-262224](https://www.sec.gov/Archives/edgar/data/1017491/000113626122000048/seelforms-8.htm)) filed by the Registrant with the Securities and Exchange Commission (the "Commission") on July 17, 2012, October 10, 2013, June 5, 2015, March 9, 2016, January 4, 2017, May 31, 2017, February 25, 2019, May 21, 2020, April 30, 2021 and January 18, 2022 (collectively, the "Prior Registration Statements"), the Registrant previously registered an aggregate of 15,641,439 shares of Common Stock under the 2012 Plan and an aggregate of 2,600,362 shares of Common Stock under the ESPP.

In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements are hereby incorporated by reference.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by the Registrant with the Commission are hereby incorporated by reference into this Registration Statement:

(a) The
Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on March 9,
2023; and

(b) The
description of the Registrant's common stock set forth in the [Registrant's Registration Statement on Form 8-A (File No. 000-22245), filed with the Commission on April 10, 2000](https://www.sec.gov/Archives/edgar/data/1017491/0001005477-00-002994-index.html) , including any amendments or reports filed for the purpose
of updating such description, including the description of our Common Stock included as Exhibit 4.12 to our Annual Report on Form 10-K
for the year ended December 31, 2022, filed with the SEC on March 9, 2023.

All other reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of the filing of such reports and documents, except as to any portion of any future annual or quarterly report to shareholders or document or current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions.

For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

You may contact the Registrant in writing or orally to request copies of the above-referenced filings, without charge (excluding exhibits to such documents unless such exhibits are specifically incorporated by reference into the information incorporated by reference into this Registration Statement). Requests for such information should be directed to:

Seelos Therapeutics, Inc.

300 Park Avenue, 2nd Floor

New York, NY 10022

(646) 293-2100

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description of Document** |
| [3.1](https://www.sec.gov/Archives/edgar/data/1017491/0001005477-97-000778-index.html) | [Amended and Restated Articles of Incorporation of the Registrant (incorporated herein by reference to Exhibit 2.1 to the Registrant's Registration Statement on Form 10-SB filed with the Securities and Exchange Commission on March 14, 1997).](https://www.sec.gov/Archives/edgar/data/1017491/0001005477-97-000778-index.html) |
| [3.2](https://www.sec.gov/Archives/edgar/data/1017491/000095013603000741/file002.txt) | [Certificate of Amendment to Articles of Incorporation of the Registrant, dated June 22, 2000 (incorporated herein by reference to Exhibit 3.2 to the Registrant's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2003).](https://www.sec.gov/Archives/edgar/data/1017491/000095013603000741/file002.txt) |
| [3.3](https://www.sec.gov/Archives/edgar/data/1017491/000114420406010273/v037542_ex3-4.htm) | [Certificate of Amendment to Articles of Incorporation of the Registrant, dated June 14, 2005 (incorporated herein by reference to Exhibit 3.4 to the Registrant's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2006).](https://www.sec.gov/Archives/edgar/data/1017491/000114420406010273/v037542_ex3-4.htm) |
| [3.4](https://www.sec.gov/Archives/edgar/data/1017491/000114420410017441/v178249_ex3-6.htm) | [Certificate of Amendment to Amended and Restated Articles of Incorporation of the Registrant, dated March 3, 2010 (incorporated herein by reference to Exhibit 3.6 to the Registrant's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).](https://www.sec.gov/Archives/edgar/data/1017491/000114420410017441/v178249_ex3-6.htm) |
| [3.5](https://www.sec.gov/Archives/edgar/data/1017491/000114420410017441/v178249_ex3-7.htm) | [Certificate of Correction to Certificate of Amendment to Amended and Restated Articles of Incorporation of the Registrant, dated March 3, 2010 (incorporated herein by reference to Exhibit 3.7 to the Registrant's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).](https://www.sec.gov/Archives/edgar/data/1017491/000114420410017441/v178249_ex3-7.htm) |
| [3.6](https://www.sec.gov/Archives/edgar/data/1017491/000114420411016743/v215636_ex3-1.htm) | [Certificate of Designation for Series D Junior-Participating Cumulative Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Registrant's Registration Statement on Form 8-A filed with the Securities and Exchange Commission on March 24, 2011).](https://www.sec.gov/Archives/edgar/data/1017491/000114420411016743/v215636_ex3-1.htm) |
| [3.7](https://www.sec.gov/Archives/edgar/data/1017491/000114420410034002/v188471_ex3-1.htm) | [Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 17, 2010).](https://www.sec.gov/Archives/edgar/data/1017491/000114420410034002/v188471_ex3-1.htm) |
| [3.8](https://www.sec.gov/Archives/edgar/data/1017491/000114420410048909/v196361_ex3-1.htm) | [Certificate of Amendment to Amended and Restated Articles of Incorporation of the Registrant, dated September 10, 2010 (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2010).](https://www.sec.gov/Archives/edgar/data/1017491/000114420410048909/v196361_ex3-1.htm) |
| [3.9](https://www.sec.gov/Archives/edgar/data/1017491/000119312513224446/d539505dex31.htm) | [Certificate of Withdrawal of Series D Junior Participating Cumulative Preferred Stock, dated May 15, 2013 (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 16, 2013).](https://www.sec.gov/Archives/edgar/data/1017491/000119312513224446/d539505dex31.htm) |

---

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description of Document** |
| [3.10](https://www.sec.gov/Archives/edgar/data/1017491/000101749116000227/exhibit31to8-konreversesto.htm) | [Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 25, 2016).](https://www.sec.gov/Archives/edgar/data/1017491/000101749116000227/exhibit31to8-konreversesto.htm) |
| [3.11](https://www.sec.gov/Archives/edgar/data/1017491/000101749117000091/apri63017ex310.htm) | [Certificate of Amendment filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.10 to the Registrant's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 2, 2017).](https://www.sec.gov/Archives/edgar/data/1017491/000101749117000091/apri63017ex310.htm) |
| [3.12](https://www.sec.gov/Archives/edgar/data/1017491/000101749118000075/apri63018ex312.htm) | [Certificate of Amendment filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.12 to the Registrant's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2018).](https://www.sec.gov/Archives/edgar/data/1017491/000101749118000075/apri63018ex312.htm) |
| [3.13](https://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_1.htm) | [Certificate of Amendment related to the Share Increase Amendment, filed January 23, 2019 (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 a.m. Eastern Time).](https://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_1.htm) |
| [3.14](https://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_2.htm) | [Certificate of Amendment related to the Name Change, filed January 23, 2019 (incorporated herein by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 a.m. Eastern Time).](https://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_2.htm) |
| [3.15](https://www.sec.gov/Archives/edgar/data/1017491/000113626120000114/exh3-16.htm) | [Certificate of Correction to Certificate of Amended and Restated Articles of Incorporation of the Registrant, dated March 25, 2020 (incorporated herein by reference to Exhibit 3.16 to the Registrant's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2020).](https://www.sec.gov/Archives/edgar/data/1017491/000113626120000114/exh3-16.htm) |
| [3.16](https://www.sec.gov/Archives/edgar/data/1017491/000113626120000124/exh3-1.htm) | [Certificate of Amendment to the Amended and Restated Articles of Incorporation of Seelos Therapeutics, Inc., filed May 18, 2020 (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 19, 2020).](https://www.sec.gov/Archives/edgar/data/1017491/000113626120000124/exh3-1.htm) |
| [3.17](https://www.sec.gov/Archives/edgar/data/1017491/000113626120000131/exh3-1.htm) | [Certificate of Correction of the Certificate of Amendment to the Amended and Restated Articles of Incorporation of Seelos Therapeutics, Inc., filed May 20, 2020 (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on May 21, 2020).](https://www.sec.gov/Archives/edgar/data/1017491/000113626120000131/exh3-1.htm) |
| [3.18](https://www.sec.gov/Archives/edgar/data/1017491/000113626121000080/exh3-1.htm) | [Certificate of Amendment to the Amended and Restated Articles of Incorporation of Seelos Therapeutics, Inc., filed May 21, 2021 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2021).](https://www.sec.gov/Archives/edgar/data/1017491/000113626121000080/exh3-1.htm) |
| [3.19](https://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_3.htm) | [Amended and Restated Bylaws, dated January 24, 2019 (incorporated herein by reference to Exhibit 3.3 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 a.m. Eastern Time).](https://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_3.htm) |
| [4.1](https://www.sec.gov/Archives/edgar/data/1017491/000114420411016740/v215638_ex4-1.htm) | [Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2011).](https://www.sec.gov/Archives/edgar/data/1017491/000114420411016740/v215638_ex4-1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1017491/000114036120008730/nc10010435x2_def14a.htm#tAPPB) | [Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan, effective May 15, 2020 (incorporated herein by reference to Appendix B to the Registrant's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 13, 2020).](https://www.sec.gov/Archives/edgar/data/1017491/000114036120008730/nc10010435x2_def14a.htm#tAPPB) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1017491/000101749114000079/apri-2014630xex101.htm) | [Form of Stock Option Grant Notice and Stock Option Agreement under the Company's 2012 Stock Long Term Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2014).](https://www.sec.gov/Archives/edgar/data/1017491/000101749114000079/apri-2014630xex101.htm) |

---

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description of Document** |
| [4.4](https://www.sec.gov/Archives/edgar/data/1017491/000114036120008730/nc10010435x2_def14a.htm#tAPPA) | [Seelos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (incorporated herein by reference to Appendix A to the Registrant's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 13, 2020).](https://www.sec.gov/Archives/edgar/data/1017491/000114036120008730/nc10010435x2_def14a.htm#tAPPA) |
| [5.1](tm238252d1_ex5-1.htm) | [Opinion of Brownstein Hyatt Farber Schreck, LLP.](tm238252d1_ex5-1.htm) |
| [23.1](tm238252d1_ex23-1.htm) | [Consent of KPMG LLP, Independent Registered Public Accounting Firm.](tm238252d1_ex23-1.htm) |
| [23.2](tm238252d1_ex5-1.htm) | [Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.1).](tm238252d1_ex5-1.htm) |
| [24.1](#Signature) | [Power of Attorney (included on signature page).](#Signature) |
| [107](tm238252d1_ex-filingfees.htm) | [Filing Fee Table](tm238252d1_ex-filingfees.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on March 9, 2023.

---

| | |
|:---|:---|
| **SEELOS THERAPEUTICS, INC.** | **SEELOS THERAPEUTICS, INC.** |
| By: | /s/ Raj Mehra, Ph.D. |
|  | Raj Mehra, Ph.D. |
|  | *President and Chief Executive Officer* |

---

**POWER OF ATTORNEY**

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below constitutes and appoints Raj Mehra, Ph.D. and Michael Golembiewski, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Raj Mehra, Ph.D. | President, Chief Executive Officer and Chairman of the Board | March 9, 2023 |
| Raj Mehra, Ph.D. | *(Principal Executive Officer)* |  |
| /s/ Michael Golembiewski | Chief Financial Officer | March 9, 2023 |
| Michael Golembiewski | (*Principal Financial and Accounting Officer)* |  |
| /s/ Margaret Dalesandro, Ph.D. | Director | March 9, 2023 |
| Margaret Dalesandro, Ph.D. |  |  |
| /s/ Brian Lian, Ph.D. | Director | March 9, 2023 |
| Brian Lian, Ph.D. |  |  |
| /s/ Daniel J. O'Connor, J.D. | Director | March 9, 2023 |
| Daniel J. O'Connor, J.D. |  |  |
| /s/ Richard W. Pascoe | Director | March 9, 2023 |
| Richard W. Pascoe |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](tm238252d1_ex5-1img001.jpg) | **Brownstein Hyatt Farber Schreck, LLP**<br> 702.382.2101 main<br> 100 North City Parkway, Suite 1600<br> Las Vegas, Nevada 89106 |

---

March 9, 2023

Seelos Therapeutics, Inc.

300 Park Avenue, 12th Floor

New York, NY 10022

Ladies and Gentlemen:

We have acted as local Nevada counsel to Seelos Therapeutics, Inc., a Nevada corporation (the "<u>Company</u>"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "<u>Registration Statement</u>") with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Act</u>"), relating to the registration of (i) 4,771,457 shares (the "<u>2012 Plan Shares</u>") of the Company's common stock, par value $0.001 per share (the "<u>Common Stock</u>"), issuable under the Company's Amended and Restated 2012 Stock Long Term Incentive Plan (as amended to date, the "<u>2012 Plan</u>"), and (ii) 1,063,421 shares (the "<u>2020 Plan Shares</u>" and together with the 2012 Plan Shares, the "<u>Shares</u>") of Common Stock issuable under the Company's 2020 Employee Stock Purchase Plan (the "<u>2020 Plan</u>" and together with the 2012 Plan, the "<u>Plans</u>"). This opinion letter is being delivered at your request pursuant to the requirements of Item 601(b)(5) of Regulation S-K under the Act.

In our capacity as such counsel, we are familiar with the proceedings taken and proposed to be taken by the Company in connection with the authorization and issuances of the Shares as contemplated by the Plans and as described in the Registration Statement. For purposes of this opinion letter, and except to the extent set forth in the opinion expressed below, we have assumed that all such proceedings have been or will be timely completed in the manner contemplated by the Plans and as presently proposed in the Registration Statement.

For purposes of issuing the opinion hereinafter expressed, we have made such legal and factual examinations and inquiries, including an examination of originals or copies certified or otherwise identified to our satisfaction as being true copies of (i) the Registration Statement, (ii) each of the Plans, (iii) the articles of incorporation and bylaws of the Company, each as amended to date, and (iv) such other agreements, instruments, corporate records and other documents as we have deemed necessary or appropriate. We have also obtained from officers and other representatives and agents of the Company and from public officials, and have relied upon, such certificates, representations and assurances as we have deemed necessary or appropriate for the purpose of issuing this opinion letter.

Without limiting the generality of the foregoing, we have, with your permission, assumed without independent verification that (i) each natural person executing any of the documents we reviewed has sufficient legal capacity to do so; (ii) all documents submitted to us as originals are authentic, the signatures on all documents we reviewed are genuine and all documents submitted to us as certified, conformed, photostatic, electronic or facsimile copies conform to the original document; (iii) all corporate records made available to us by the Company, and all public records we have reviewed, are accurate and complete; and (iv) after any issuance of Shares, the total number of issued and outstanding shares of Common Stock, together with the total number of shares of Common Stock then reserved for issuance or obligated to be issued by the Company pursuant to any agreement or arrangement or otherwise, including the Plans, will not exceed the total number of shares of Common Stock then authorized under the Company's articles of incorporation.

**www.bhfs.com**

Seelos Therapeutics, Inc.

March 9, 2023

We are qualified to practice law in the State of Nevada. The opinion set forth herein is expressly limited to and based exclusively on the general corporate laws of the State of Nevada, and we do not purport to be experts on, or to express any opinion with respect to the applicability thereto or the effect thereon of, the laws of any other jurisdiction. We express no opinion concerning, and we assume no responsibility as to laws or judicial decisions related to, or any orders, consents or other authorizations or approvals as may be required by, any federal laws, rules or regulations, including, without limitation, any federal securities laws, rules or regulations, or any state securities or "blue sky" laws, rules or regulations.

Based on the foregoing and in reliance thereon, and having regard to legal considerations and other information that we deem relevant, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The 2012 Plan Shares have been duly authorized and, when and to the extent issued in accordance with all applicable terms and conditions set forth in the 2012 Plan and in exchange for the consideration required thereunder, and as described in the Registration Statement, the 2012 Plan Shares will be validly issued, fully paid and non-assessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The 2020 Plan Shares have been duly authorized and, when and to the extent issued in accordance with all applicable terms and conditions set forth in the 2020 Plan and in exchange for the consideration required thereunder, and as described in the Registration Statement, the 2020 Plan Shares will be validly issued, fully paid and non-assessable.

The opinion expressed herein is based upon the applicable laws of the State of Nevada and the facts in existence on the date of this opinion letter. In delivering this opinion letter to you, we disclaim any obligation to update or supplement the opinion set forth herein or to apprise you of any changes in any laws or facts after such time as the Registration Statement is declared effective. No opinion is offered or implied as to any matter, and no inference may be drawn, beyond the strict scope of the specific issues expressly addressed by the opinion set forth herein.

Seelos Therapeutics, Inc.

March 9, 2023

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Brownstein Hyatt Farber Schreck, LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated March 9, 2023, with respect to the consolidated financial statements of Seelos Therapeutics, Inc., incorporated herein by reference.

/s/ KPMG LLP

Short Hills, New Jersey

March 9, 2023

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Seelos Therapeutics, Inc.**

(Exact name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security<br> Type** | **Security Class<br> Title** | **Fee<br> Calculation<br> Rule** | **Amount<br> Registered<sup>(1)</sup>** | **Proposed<br> Maximum<br> Offering Price Per<br> Unit** | **Maximum Aggregate<br> Offering Price** | **Fee Rate** | **Amount of<br> Registration Fee** |
| Equity | Common Stock, par value $0.001 per share, reserved for issuance pursuant to the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan | 457(h) | 4771457<sup>(2)</sup> | $0.65<sup>(3)</sup> | $3101447.05 | 0.00011020 | $341.78 |
| Equity | Common Stock, par value $0.001 per share, reserved for issuance pursuant to the Seelos Therapeutics, Inc. 2020 Employee Stock Purchase Plan | 457(h) | 1063421<sup>(4)</sup> | $0.5525<sup>(5)</sup> | $587540.10 | 0.00011020 | $64.75 |
| **Total Offering Amounts** | **Total Offering Amounts** |  |  |  | $3688987.15 |  | $406.53 |
| **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |  |  |  |
| **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |  |  |
| **Net Fee Due** | **Net Fee Due** |  |  |  |  |  | $406.53 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 (the "Registration Statement") shall also cover any additional shares of common stock, $0.001 par value per share (the "Common Stock"), of the Registrant that become issuable under the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the "2012 Plan") and the Seelos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant's outstanding shares of Common Stock.

(2) Represents shares of Common Stock that were automatically added to the shares reserved for issuance under the 2012 Plan on January 1, 2023 pursuant to an "evergreen" provision contained in the 2012 Plan. The 2012 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of Common Stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a number of shares of Common Stock set by the Registrant's board of directors on or prior to each such January 1.

(3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rules 457(c) and
 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and the proposed maximum aggregate
 offering price with respect to these shares are calculated based on $0.65 per share, the average of the high and low prices of the
 Common Stock as reported on the Nasdaq Capital Market on March 7, 2023, a date within five business days prior to the filing of this
 Registration Statement.

(4) Represents shares of Common Stock that were automatically added
to the shares reserved for issuance under the ESPP on January 1, 2023 pursuant to an "evergreen" provision contained
in the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for
issuance under the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1,
2030. The number of shares added each year will be equal to the lesser of (a) 1% of the number of shares of Common Stock issued
and outstanding on the immediately preceding December 31, and (b) a number of shares of Common Stock set by the Registrant's
board of directors or the Registrant's compensation committee of the board of directors on or prior to each such January 1.

(5) Estimated solely for the purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and the proposed maximum aggregate offering price with respect to these shares are calculated based on 85% of $0.65 per share, the average of the high and low prices of the Common Stock as reported on the Nasdaq Capital Market on March 7, 2023, a date within five business days prior to the filing of this Registration Statement. Pursuant to the ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the Common Stock on (i) the first day of the offering period or (ii) the purchase date.